Each disease area and drug program in our pipeline takes us one step closer to transforming preclinical R&D using computational biology, real-world evidence data, and fast experimentation cycles to discover and validate novel biomarkers and targets. By doing early discovery and pre-clinical steps more efficiently than traditional approaches we aim to deliver better medicines, faster.